Meng, Xiao-Wei, Jie Wang, and Qing-Wen Ma
The American Association of Clinical Endocrinology (AACE) 2022 obesity guidelines, available at aace.com, explicitly list GLP-1 receptor agonists as second-line pharmacotherapy for patients with insulin resistance or metabolic obesity
To reduce irritation and lumps, it helps to rotate injection sites (dont inject the same spot repeatedly), inject into healthy skin (avoid bruised, scarred, inflamed, or irritated areas), and keep your routine consistent (many protocols are taken in the morning)
The Takeaway Celebrities, including Serena Williams and Charles Barkley, have spoken openly about taking GLP-1 medications, helping reduce stigma
Novo Nordisk, which competes with Lilly with its drugs Ozempic and Wegovy, is in the Triple G game as well, reporting average weight loss of almost 20% after 24 weeks in a mid-stage study of another experimental drug in China last month